Journal of Gerontological Nursing

NEW FOR NOW

Abstract

Fish Oil Capsules

Squibb®Mark, the consumer products division of Squibb United States, introduced Proto-Chol*" gelcaps -concentrated natural fish oil in soft gelatin capsules. The product is a dietary supplement for use in a total nutritional and lifestyle program, which should include a proper diet, exercise, a healthy lifestyle, and regular medical check-ups.

Proto-Chol ™ is rich in Omega-3 fatty acids, which are derived from deep-sea, cold-water fish. Studies suggest that two of these fatty acids - eicosapentaenoic acid (EPA) and docosahexanenoic acid (DHA) - may help control blood cholesterol and triglycéride levels.

"In general, Americans don't get enough Omega-3s from the amount of fish they eat," said Artemis Simopoulos, MD, immediate past chairperson of the National Institutes of Health Nutrition Coordinating Committee and an internationally recognized expert on Omega-3s.

"Squibb®Mark is taking a very responsible approach by introducing the Omega-3s within the context of a total nutritional program," Dr Simopoulos added. "The recommended serving size of Proto-Chol "" is one to two gelcaps per meal - which adds between 0. 9 and l.Sgof Omega-3s each day to the proper nutritional diet. This provides a convenient means of supplementing the diet with Omega-3 s."

Proto-Chol™ is offered in packages of 60 and 90 gelcaps, at an average retail price of $6.49 and $8.49, respectively.

For more information circle #3…

Foot Pump Dispenser System

Stuart Pharmaceuticals has announced the introduction of an innovative foot pump dispenser system for Hibiclens® (chlorhexidine gluconate), the only antiseptic/antimicrobial skin cleanser found effective by the US Food and Drug Administration.

The new device offers hospitals a choice of delivery - Hibiclens in either liquid or mechanically generated foam - at the turn of a control switch located on top of the pump head.

The new foot pump dispenser system has been designed exclusively for use with Hibiclens liquid and, according to Stuart, is virtually maintenance-free.

The new Hibiclens foot pump dispenser system became available October 1, 1986. For more information, contact your local Stuart representative.

For more information circle #1

VePesid Available Commercially

Bristol-Myers Company has announced the commercial availability of VePesid (etoposide) for use in combination chemotherapy as first-line treatment of a form of lung cancer known as small cell lung carcinoma. This marks the first time in over a decade that a chemotherapeutic agent for the treatment of this rapidly lethal form of lung cancer has been made available for this indicated use.

VePesid was introduced in the United States in December 1983 and was originally indicated for use as treatment of te stic u lar cancers that did not respond to standard chemotherapy. VePesid is marketed by the Bristol-Myers Oncology Division, a part of the Bristol-Myers United States Pharmaceutical Group.

According to EJ Fox, MD, vice president and medical director, BristolMyers US Pharmaceutical Group, "VePesid is an important first-line agent for the treatment of small cell lung cancer. The Food and Drug Administration Oncologie Drugs Advisory Committee was unanimous in its favorable evaluation of VePesid for use in combination with other approved chemotherapeutic agents as a first-line treatment in patients with this common and rapidly lethal form of cancer.

In making its recommendation, the committee concluded that VePesidcontaining regimens offer a statistically significant survival advantage in patients with extensive small cell lung cancer. "

The FDA Oncologie Drugs Advisory Committee is a peer review group of experts with responsibility for making recommendations on the safety and efficacy of new cancer drugs, and new therapeutic uses for existing cancer drugs. An oral form of VePesid was also favorably evaluated by this committee, but has not yet been the subject of an FDA determination.

Dr. Fox continued, "VePesid is currently given by infusion (intravenously over a 30 to 60 minute time period), and often administered on an outpatient basis. The use and convenience of administering VePesid on an outpatient basis is enhanced by its predictable toxic ity profile.

The major toxicity of this drug is bone marrow suppression, as is the case with most chemotherapeutic agenis. in view of the increasing national trend toward outpatient therapies, the predictable toxicity profile of VePesid is an important factor for the use of this drug."

Rx more information circle #2

Fish Oil Capsules

Squibb®Mark, the consumer products division of Squibb United States, introduced Proto-Chol*" gelcaps -concentrated natural fish oil in soft gelatin capsules. The product is a dietary supplement for use in a total nutritional and lifestyle program, which should include a proper diet, exercise, a healthy lifestyle, and regular medical check-ups.

Proto-Chol ™ is rich in Omega-3 fatty acids, which are derived from deep-sea, cold-water fish. Studies suggest that two of these fatty acids - eicosapentaenoic acid (EPA) and docosahexanenoic acid (DHA) - may help control blood cholesterol and triglycéride levels.

"In general, Americans don't get enough Omega-3s from the amount of fish they eat," said Artemis Simopoulos, MD, immediate past chairperson of the National Institutes of Health Nutrition Coordinating Committee and an internationally recognized expert on Omega-3s.

"Squibb®Mark is taking a very responsible approach by introducing the Omega-3s within the context of a total nutritional program," Dr Simopoulos added. "The recommended serving size of Proto-Chol "" is one to two gelcaps per meal - which adds between 0. 9 and l.Sgof Omega-3s each day to the proper nutritional diet. This provides a convenient means of supplementing the diet with Omega-3 s."

Proto-Chol™ is offered in packages of 60 and 90 gelcaps, at an average retail price of $6.49 and $8.49, respectively.

For more information circle #3

10.3928/0098-9134-19870101-11

Sign up to receive

Journal E-contents